NeoBiocon

NeoBiocon is a pharmaceutical company headquartered in the United Arab Emirates, originally established in 2008 as a joint venture between India's Biocon and the UAE's Neopharma. The company specializes in the marketing and distribution of advanced biopharmaceuticals and specialty small molecule drugs across the Gulf Cooperation Council (GCC) region. Its product portfolio primarily features biosimilars and branded generics targeting chronic diseases such as diabetes, oncology, cardiology, and autoimmune disorders. In 2021, Biocon divested its 49% stake in the venture to Neopharma, making NeoBiocon a wholly-owned subsidiary of the Abu Dhabi-based pharmaceutical group. NeoBiocon remains a key player in the Middle Eastern healthcare market, providing access to high-quality, affordable therapeutic solutions. The company leverages Neopharma's local manufacturing capabilities and Biocon's extensive R&D pipeline to serve patients in the region.